34 results about "Diabetes Therapy" patented technology

A method of diabetes analysis is provided. A plurality of glucose level readings for a user is received. The plurality of blood glucose level readings are analyzed to generate a report. The report includes a first chart along a 24-hour timeline indicating the plurality of glucose level readings, and a second chart having at least one of infusion device settings and active insulin levels corresponding to the 24-hour timeline of the first chart.

An electronic computing device as presented here includes a device communications layer, a processor device, and a reporting layer. The device communications layer receives sensor data for a user of an insulin infusion device, wherein the sensor data indicates blood glucose levels of the user for a specified period of time, and over a plurality of days. The processor device analyzes the received sensor data to detect an event occurrence indicative of a correctable basal rate setting of the insulin infusion device. The reporting layer generates a report containing a graphical representation of the received sensor data and a recommendation to adjust a basal rate setting of the insulin infusion device, wherein the recommendation is intended to address the detected event occurrence.

The present invention relates to methods for treating and/or preventing metabolic diseases comprising the combined administration of a DPP-4 inhibitor and a long-acting insulin. The invention further relates to a DPP-4 inhibitor for subcutaneous or transdermal use.

A system and method to provide guidance for diabetes therapy includes determining glycemic risks based on an analysis of glucose data. The analysis includes visualization of a glucose median, the variability of glucose in a patient, and the risk of hypoglycemia. An Advanced Daily Patterns report includes a visualization of an ambulatory glucose profile and a glucose control measure. The glucose control measure provides a highly visible and understandable display of the glucose condition of a patient visually expressed in the categories of low glucose, median glucose, and glucose variability.

The invention relates to a kind of method for synthesizing midbody N-(2-ethoxyl)-glucosamine of diabetes therapy medicine miglitol alcohol. The existing literature has no synthesizing method recordation of midbody N-(2-ethoxyl)-glucosamine. The reaction steps of the invention are as follows: A) Stuff casting: in autoclave, add D-glucose and ethanolamine according to molar ratio of D-glucose/ethanolamine with 1/1.05-1.10; then add 70-95% alcohols solvent with 5-10 times weight of glucose; and after nitrogen displace, add 5%Pd-CaCO3-1-5%Pb catalyst with 2-10% weight of glucose; inject high purity hydrogen, keep hydrogen pressure to 2-3Mpa, and then intensify the temperature slowly up to reaction temperature; B) Reaction: control reaction temperature in 35-45deg.C, hydrogen pressure in 2-4Mpa, and reaction by 20-24 hours; C) Get white pulverous solid by after-treatment. The invention selects the appropriate catalyst and reasonable hydrogenization technology, so that it can make the reaction condition of glucose and ethanolamine with relatively gentleness, make the reaction easy to proceed, make by-product and other impurity generated badly, and also it has high conversion rate, and more than or equal to 98% purity.

A diabetes therapy device is disclosed herein, which includes a profile memory storing a parameter profile and a dedicated reference time mark. The parameter profile defines at least one parameter that is associated with insulin administration as a function of time for a generally circadian chronobiological cycle. The reference time mark indicates the beginning of the circadian chronobiological cycle and initializes a running time. Insulin amounts to be administered are determined as a function of the running time in accordance with a current matching of the parameter profile. A modified matching based on the reference time mark and an upcoming trigger time is computed and is time-shifted from the current matching, wherein the modified matching is applied by making the modified matching the current matching, such that future insulin amounts to be administered are determined in accordance with the modified matching.

The present invention relates generally to the field of human genetics. Specifically, the present invention relates to methods and materials used to isolate and detect human diabetes mellitus predisposing gene, specifically the angiotensinogen (AGT) gene, some mutant alleles of which cause susceptibility to insulin-dependent diabetes mellitus (IDDM). More specifically, the invention relates to gernline mutations in the AGT gene and their use in the diagnosis of predisposition to diabetes. The invention also relates to the prophylaxis and/or therapy of diabetes associated with a mutation in the AGT gene. The invention further relates to the screening of drugs for diabetes therapy. Finally, the invention relates to the screening of the AGT gene for mutations, which are useful for diagnosing the predisposition to diabetes.

The invention provides a recombinant engineering bacterium for efficiently expressing a liraglutide precursor and an application of the recombinant engineering bacterium. According to the invention, asignal peptide and an enterokinase restriction enzyme cutting site are designed at the N end of a liraglutide precursor molecule Arg34G LP-1 (7-37), the C end is connected with termination codon, a target gene is formed, then, the target gene is inserted between two restriction enzyme cutting sites of an expression vector; the recombinant engineering bacterium for expressing the liraglutide precursor is constructed, the engineering bacterium is subjected to high-density fermentation culture and is expressed in the form of an inclusion body of a fusion protein, the expression quantity of the recombinant fusion protein is high, the recombinant fusion protein accounts for about 25%-35% of the total protein of the bacterium, and the expression quantity of the inclusion body of a target protein reaches 15-20g/L. The inclusion body is low in impurity protein content, beneficial to separation and purification, and high in purification efficiency and good in stability, the production cost isgreatly reduced, the production efficiency is improved, and the inclusion body has the good application prospect in the field of diabetes treatment medicine preparation.

A pharmaceutical composition includes at least two of agents I)-iii), wherein agent i) is selected from the group consisting of an insulin, an insulin analog, a physiologically active fragment of said insulin and a physiologically active fragment of said insulin analog, agent ii) is selected from the group consisting of an insulin-related peptide, an insulin-related peptide analog, a physiologically active insulin-related peptide fragment and a physiologically active insulin-related peptide analog fragment, and agent iii) is an insulin sensitizer.

Rapidly disintegrating oral dosage forms for the application of active agent combinations for diabetes therapy. The dosage forms contain at least two active agents suitable for treating type-2 diabetes. The antidiabetic active agents are selected from the group comprising sulfonylureas, glitazones, glinides, biguanides, and absorption-delaying agents. The use of the active agent combination to produce an oral dosage form for the treatment of diabetes, a method for the therapeutic treatment of diabetes, and a method for the production of a sheet-like dosage form are also disclosed.

The invention relates to a dietary supplement comprising alpha keto acids for supporting diabetes therapy. The invention relates to a preparation used as a dietary supplement comprising alpha keto acids for supporting therapy of diabetes mellitus type II (DM). The preparation comprises at least one of the alpha keto acids from the group alpha ketoisocaproate (KIC), alpha ketoisovalerate (KIV), alpha keto beta methylvalerate (KMV) and alpha keto glutarate (AKG).

Described herein is a novel, mitochondrial encoded, open reading frame, that leads to the production of a new mitochondrial peptide. Residing within the ND-Two subunit, a specific small nucleotide polymorphism disrupts expression of this mitochondrial peptide, and is correlated with an increase in obesity and diabetes, particularly in certain ethnic populations. In vitro administration of the peptide increases insulin secretion, decreases fat accumulation and improves glucose uptake in muscle cell. Antibodies generated against the peptide can be used for detecting peptide deficiency, in addition to SNP detection, supporting diagnostic approaches. In vivo studies further revealed that administration of the peptide improves glucose tolerance, thereby providing a new therapeutic avenue for a novel diabetes therapy and decreases bodyweight, thus serving as a novel obesity therapy. Generation of synthetic analogs further enhance or abrogated activity relative to the natural peptide.

This invention is related to a sugar-like chemical composition for use in diabetes therapy. Particularly, the present invention teaches the use of monosaccharide-like glycylated sugar alcohol compounds to block or reduce sugar absorption in diabetes patients, so as to prevent the risk of hyperglycemia symptoms. The novelty of the present invention is that glycylated sugar alcohols were found to be useful for treating Diabetes mellitus. In addition, the present application discloses a method for producing these glycylated sugar alcohols. In sum, the present invention includes not only a kind of sugar-like chemical composition for use in treating diabetes but also discloses a state-of-the-art protocol and methodology for producing such a composition via glycylation of sugars and sugar alcohols.

The invention is concerned with the method of preparation of the alpha-glycosidase inhibitor extracts from walnut. It contents the active ingradient of the shell and kernel of the walnut (also includes Juglans regia L., Juglans cathayensis Dode, and Juglans mandshurica Maxim). Thealpha-glycosidase inhibitor is extracted from the draff after oil fired by water, alcohol, or water-alcohol solution, through filtration, concentration, and drying at last. It can use for prepareing health products for diabetes therapy or blood suger controlling.